Navigation Links
Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company, announced today that preliminary findings from its ongoing Phase II dermatological study show topical treatment with AVR118 appears to have clinical activity in reducing inflammation and redness associated with surgical incisions or dermatologic dermabrasion.

The Phase II open label dermatological study is evaluating the activity of a topically applied spray formulation of AVR 118 as an anti-inflammatory and regenerative healing agent. The first cohort of patients examined underwent dermabrasion for the treatment of severe acne. Following the procedure, AVR118 was applied directly to one half of the inflamed facial tissue. The other half of the face remained untreated. A preliminary examination of five patients demonstrated visible improvement on the treated side of their face. The treated area showed less inflammation as well as a reduction in the redness and swelling of acne lesions.

The second cohort of patients examined underwent plastic surgery that resulted in a minimum of two bilateral surgical incisions. AVR118 was applied topically to one wound and the second wound served as an untreated control. In early results from two patients, one patient demonstrated a decrease in inflammation on the treated side.

"I am very encouraged by this data. The response we've seen thus far indicates that AVR118 may have beneficial activity in both sets of patients," said Stephen M. Elliston, President and Chief Executive Officer. "A preliminary and unexpected result was the reduction of the inflammatory symptoms of acne. We plan to amend the protocol to include patients being treated solely for acne, given the potential of this market," added Elliston.

Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives b y researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com.

Contact

The Signature Agency
Gayle Challinor, 800-870-8700/919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result after ... (-0.22) before and after dilution Cash flow from operating activities ... ... 0.4 (0.4) million Operating result amounted to SEK -39.5 (-29.5) ...
(Date:2/24/2017)... , Feb. 24, 2017 Research and ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... a CAGR of around 23.8% over the next decade to reach ... the market estimates and forecasts for all the given segments on ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... Today, A' Design Awards & Competition ... Social Design Awards. , The 7th A' Social Design Award is open ... worldwide with realized projects and conceptual works. , The first phase of the ...
(Date:2/26/2017)... , ... February 26, 2017 ... ... a new technology standard in staffing, scheduling, and reporting for healthcare organizations. ... predict activity throughout the entire staffing process. StaffBridge technology improves staffing efficiency, ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Liberty University, has officially announced the appointment of Peter A. Bell, DO, MBA, ... Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
Breaking Medicine News(10 mins):